• Corvus Pharmaceuticals director David Scott Moore bought 21,700 shares at USD 11.53, lifting his direct stake to 21,700 shares.
• Moore also received stock options covering 15,000 shares with an exercise price of USD 11.6.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001610717-26-000223), on June 15, 2026, and is solely responsible for the information contained therein.